Anti-biotin antibodies and methods of use

Patent metadata

Field	Value
Publication number	US-9765153-B2
Application number	US-201414576916-A
Country	US
Kind code	B2
Filing date	Dec 19, 2014
Priority date	Jul 4, 2012
Publication date	Sep 19, 2017
Grant date	Sep 19, 2017

Abstract

The invention provides anti-biotin antibodies and methods of using the same.

First claim

What is claimed is:

1. An anti-biotin antibody, wherein the antibody comprises (a) a heavy chain hyper variable region 1 (HVR-H1) comprising the amino acid sequence of SEQ ID NO: 09; (b) a HVR-H2 comprising the amino acid sequence of SEQ ID NO: 10; (c) a HVR-H3comprising the amino acid sequence of SEQ ID NO: 11; (d) a light chain hyper variable region 1 (HVR-L1) comprising the amino acid sequence of SEQ ID NO: 13; (e) a HVR-L2 comprising the amino acid sequence of SEQ ID NO: 14; (f) a HVR-L3 comprising the amino acid sequence of SEQ ID NO: 15.

2. The antibody of claim 1 comprising at position 24 of the heavy chain variable domain numbered according to Kabat the amino acid residue serine or comprising at position 73 of the heavy chain variable domain numbered according to Kabat the amino acid residue threonine.

3. The antibody of claim 1 comprising at position 60 of the heavy chain variable domain numbered according to Kabat the amino acid residue alanine and at position 61 of the heavy chain variable domain numbered according to Kabat the amino acid residue glutamine.

4. The antibody of claim 1 comprising
(a) a variable heavy chain domain (VH) sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 12;
(b) a variable light chain domain (VL) sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 16; or
(c) a VH sequence as in (a) and a VL sequence as in (b),
wherein the amino acid residue at position 24 of the heavy chain variable domain numbered according to Kabat is serine or the amino acid residue at position 73 of the heavy chain variable domain numbered according to Kabat is threonine.

5. The antibody of claim 2 , comprising a VH sequence of SEQ ID NO: 12.

6. The antibody of claim 2 , comprising a VL sequence of SEQ ID NO: 16.

7. An antibody comprising a VH sequence of SEQ ID NO: 12 and a VL sequence of SEQ ID NO: 16.

8. The antibody of claim 1 , wherein the antibody is a full length IgG1 antibody or a full length IgG4 antibody.

9. The antibody of claim 1 , wherein the antibody is a monoclonal antibody.

10. The antibody of claim 1 , wherein the antibody is an antibody fragment that binds biotin.

11. A pharmaceutical formulation comprising the antibody of claim 1 and a pharmaceutically acceptable carrier.

12. The antibody of claim 1 , wherein the antibody is humanized.

13. The antibody of claim 1 comprising at position 24 of the heavy chain variable domain numbered according to Kabat the amino acid residue serine and comprising at position 73 of the heavy chain variable domain numbered according to Kabat the amino acid residue threonine.

14. The antibody of claim 1 , wherein the antibody is conjugated to one or more cytotoxic agents in an immunoconjugate.

15. The antibody of claim 1 , wherein the antibody further comprises a label.

16. A complex comprising the antibody of claim 1 and a biotinylated compound.

17. A method of delivering a biotinylated compound in an individual to the surface of a cell comprising administering to the individual an effective amount of the complex of claim 16 .

18. A multispecific antibody comprising (a) a heavy chain hyper variable region 1 (HVR-H1) comprising the amino acid sequence of SEQ ID NO: 09; (b) a HVR-H2 comprising the amino acid sequence of SEQ ID NO: 10; (c) a HVR-H3comprising the amino acid sequence of SEQ ID NO: 11; (d) a HVR-L1 comprising the amino acid sequence of SEQ ID NO: 13: (e) a HVR-L2 comprising the amino acid sequence of SEQ ID NO: 14; (f) a HVR-L3 comprising the amino acid sequence of SEQ ID NO: 15.

19. The multispecific antibody of claim 18 , wherein the antibody further binds to a cell surface molecule.

20. A complex comprising the antibody of claim 18 and a biotinylated compound.

Assignees

• Hoffmann La Roche

Inventors

• Brinkmann Ulrich
• Georges Guy
• Grote Michael
• Hoffmann Eike

Classifications

• C07K16/44 Primary

  against material not provided for elsewhere {, e.g. haptens, metals, DNA, RNA, amino acids} · CPC title

• A61K47/6801

  Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent · CPC title

• C07K2317/55

  Fab or Fab' · CPC title

• C07K2299/00

  Coordinates from 3D structures of peptides, e.g. proteins or enzymes · CPC title

• C07K2317/24

  containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered · CPC title